Ore Pharmaceuticals, Inc.
Records under this name other than patents Ore Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Ore Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,492,109 | Susceptibility mutation 6495delGC of BRCA2 Formerly held Term ended Term ended Sep 21, 2018 · From the USPTO record | Term ended | Term ended Sep 21, 2018 | From the USPTO record |
| US 6,130,322 | Coding sequences of the human BRCA1 gene Formerly held Term ended Term ended May 6, 2018 · From the USPTO record | Term ended | Term ended May 6, 2018 | From the USPTO record |
| US 6,083,698 | Cancer susceptibility mutations of BRCA1 Formerly held Term ended Term ended Dec 11, 2017 · From the USPTO record | Term ended | Term ended Dec 11, 2017 | From the USPTO record |
| US 6,051,379 | Cancer susceptibility mutations of BRCA2 Formerly held Term ended Term ended Dec 2, 2017 · From the USPTO record | Term ended | Term ended Dec 2, 2017 | From the USPTO record |
| US 6,838,256 | Coding sequences of the human BRCA1 gene Formerly held Term ended Term ended Aug 12, 2016 · From the USPTO record | Term ended | Term ended Aug 12, 2016 | From the USPTO record |
| US 6,951,721 | Method for Determining the Haplotype of a Human BRCA1 Gene Formerly held Term ended Ended no later than May 9, 2016 · Low confidence | Term ended | Ended no later than May 9, 2016 | Low confidence |
| US 6,686,163 | Coding sequence haplotype of the human BRCA1 gene Formerly held Lapsed on the fee record Ended Feb 3, 2016 · From the USPTO record | Lapsed on the fee record | Ended Feb 3, 2016 | From the USPTO record |
| US 7,842,709 | Method for treating inflammatory diseases of the digestive tract Lapsed on the fee record Ended Nov 30, 2014 · From the USPTO record | Lapsed on the fee record | Ended Nov 30, 2014 | From the USPTO record |
| US 7,790,719 | Modulators of melanocortin receptor Lapsed on the fee record Ended Sep 7, 2014 · From the USPTO record | Lapsed on the fee record | Ended Sep 7, 2014 | From the USPTO record |
| US 7,375,125 | MELANOCORTIN-4 Receptor Binding Compounds and Methods of Use Thereof Lapsed on the fee record Ended May 20, 2012 · Medium confidence | Lapsed on the fee record | Ended May 20, 2012 | Medium confidence |